Selected article for: "functional receptor and SARS spike"
Author: Yasunori Watanabe; Joel D. Allen; Daniel Wrapp; Jason S. McLellan; Max Crispin
Title: Site-specific analysis of the SARS-CoV-2 glycan shield
  • Document date: 2020_3_28
    • ID: 63j4qc7d_15
    Snippet: Shielding of the receptor binding sites on the SARS-CoV-2 spike by proximal glycosylation sites (N165, N234, N343) can be observed, especially when the receptor binding domain is in the "down" conformation. The shielding of receptor binding sites by glycans is a common feature of viral glycoproteins and has been observed for SARS-CoV S 4,8 , HIV-1 Env 31 , influenza HA 32,33 , and LASV GPC 21 . Given the functional constraints of receptor binding.....
    Document: Shielding of the receptor binding sites on the SARS-CoV-2 spike by proximal glycosylation sites (N165, N234, N343) can be observed, especially when the receptor binding domain is in the "down" conformation. The shielding of receptor binding sites by glycans is a common feature of viral glycoproteins and has been observed for SARS-CoV S 4,8 , HIV-1 Env 31 , influenza HA 32,33 , and LASV GPC 21 . Given the functional constraints of receptor binding sites and the subsequent low mutation rates of these residues, it is likely that there has been selective pressure to utilize N-linked glycans as a method to camouflage one of the most conserved and potentially vulnerable areas of their respective glycoproteins 34, 35 .

    Search related documents:
    Co phrase search for related documents
    • bind domain and receptor bind site: 1
    • bind domain and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
    • bind domain and selective pressure: 1
    • bind domain and viral glycoprotein: 1, 2, 3
    • bind site and glycosylation site: 1
    • bind site and receptor bind domain: 1
    • bind site and receptor bind site: 1, 2, 3, 4, 5, 6, 7, 8
    • bind site and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • bind site and SARS spike bind site: 1, 2
    • bind site and viral glycoprotein: 1, 2, 3
    • common feature and SARS spike: 1, 2, 3, 4, 5
    • common feature and selective pressure: 1
    • common feature and viral glycoprotein: 1
    • glycosylation site and receptor bind site: 1
    • glycosylation site and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • glycosylation site and selective pressure: 1, 2
    • glycosylation site and viral glycoprotein: 1, 2, 3, 4, 5, 6, 7
    • low mutation and SARS spike: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • low mutation and selective pressure: 1, 2, 3